PL206627B1
(en)
*
|
1999-01-22 |
2010-09-30 |
Kirin Pharma Kk |
Quinazoline derivative, its use and pharmaceutical composition
|
US7135466B2
(en)
*
|
1999-12-24 |
2006-11-14 |
Kirin Beer Kabushiki Kaisha |
Quinoline and quinazoline derivatives and drugs containing the same
|
US8022058B2
(en)
|
2000-05-10 |
2011-09-20 |
The Trustees Of Columbia University In The City Of New York |
Agents for preventing and treating disorders involving modulation of the RyR receptors
|
US6489125B1
(en)
*
|
2000-05-10 |
2002-12-03 |
The Trustees Of Columbia University In The City Of New York |
Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
|
US7393652B2
(en)
|
2000-05-10 |
2008-07-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
|
US7718644B2
(en)
|
2004-01-22 |
2010-05-18 |
The Trustees Of Columbia University In The City Of New York |
Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
|
US20040048780A1
(en)
*
|
2000-05-10 |
2004-03-11 |
The Trustees Of Columbia University In The City Of New York |
Method for treating and preventing cardiac arrhythmia
|
US20060293266A1
(en)
*
|
2000-05-10 |
2006-12-28 |
The Trustees Of Columbia |
Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
|
US20040229781A1
(en)
*
|
2000-05-10 |
2004-11-18 |
Marks Andrew Robert |
Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
|
US7879840B2
(en)
|
2005-08-25 |
2011-02-01 |
The Trustees Of Columbia University In The City Of New York |
Agents for preventing and treating disorders involving modulation of the RyR receptors
|
ATE399766T1
(en)
*
|
2000-10-20 |
2008-07-15 |
Eisai R&D Man Co Ltd |
AROMATIC HETEROCYCLES CONTAINING NITROGEN
|
KR100879669B1
(en)
|
2001-04-27 |
2009-01-21 |
기린 파마 가부시끼가이샤 |
Quinoline Derivative Having Azolyl Group and Quinazoline Derivative
|
CA2454538A1
(en)
*
|
2001-06-22 |
2003-01-03 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
|
US7495104B2
(en)
*
|
2001-10-17 |
2009-02-24 |
Kirin Beer Kabushiki Kaisha |
Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
|
EP1535910A4
(en)
*
|
2002-05-01 |
2007-03-14 |
Kirin Brewery |
Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
|
CA2491191C
(en)
|
2002-07-15 |
2014-02-04 |
Exelixis, Inc. |
Receptor-type kinase modulators and methods of use
|
EP1559715B1
(en)
*
|
2002-10-21 |
2007-09-26 |
Kirin Beer Kabushiki Kaisha |
N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form
|
EP1566379A4
(en)
*
|
2002-10-29 |
2005-11-09 |
Kirin Brewery |
QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
|
US7544678B2
(en)
*
|
2002-11-05 |
2009-06-09 |
The Trustees Of Columbia University In The City Of New York |
Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
|
AU2003292838A1
(en)
*
|
2002-12-27 |
2004-07-29 |
Kirin Beer Kabushiki Kaisha |
Therapeutic agent for wet age-related macular degeneration
|
JP2007525165A
(en)
|
2003-03-07 |
2007-09-06 |
トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク |
Type 1 ryanodine receptor based method
|
EP1604665B1
(en)
*
|
2003-03-10 |
2011-05-11 |
Eisai R&D Management Co., Ltd. |
C-kit kinase inhibitor
|
ES2925655T3
(en)
*
|
2003-09-26 |
2022-10-19 |
Exelixis Inc |
c-Met modulators and methods of use
|
US7683172B2
(en)
|
2003-11-11 |
2010-03-23 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for preparing the same
|
US20050171172A1
(en)
*
|
2003-11-13 |
2005-08-04 |
Ambit Biosciences Corporation |
Amide derivatives as PDGFR modulators
|
US8710045B2
(en)
|
2004-01-22 |
2014-04-29 |
The Trustees Of Columbia University In The City Of New York |
Agents for preventing and treating disorders involving modulation of the ryanodine receptors
|
EP1711495A2
(en)
*
|
2004-01-23 |
2006-10-18 |
Amgen Inc. |
Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
KR20070053205A
(en)
|
2004-09-17 |
2007-05-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
Medicinal composition
|
CA2603748A1
(en)
*
|
2005-04-06 |
2006-10-12 |
Exelixis, Inc. |
C-met modulators and methods of use
|
TW200740820A
(en)
*
|
2005-07-05 |
2007-11-01 |
Takeda Pharmaceuticals Co |
Fused heterocyclic derivatives and use thereof
|
WO2007015569A1
(en)
*
|
2005-08-01 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
Method for assay on the effect of vascularization inhibitor
|
US7704990B2
(en)
|
2005-08-25 |
2010-04-27 |
The Trustees Of Columbia University In The City Of New York |
Agents for preventing and treating disorders involving modulation of the RyR receptors
|
CN102716490A
(en)
*
|
2005-09-01 |
2012-10-10 |
卫材R&D管理有限公司 |
Method for preparation of pharmaceutical composition having improved disintegradability
|
AU2006309551B2
(en)
*
|
2005-11-07 |
2012-04-19 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
WO2007061130A1
(en)
*
|
2005-11-22 |
2007-05-31 |
Eisai R & D Management Co., Ltd. |
Anti-tumor agent for multiple myeloma
|
EP2036557B1
(en)
*
|
2006-05-18 |
2015-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
JPWO2008001956A1
(en)
*
|
2006-06-29 |
2009-12-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Liver fibrosis treatment
|
WO2008026748A1
(en)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
US8962655B2
(en)
|
2007-01-29 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
CN105777776B
(en)
|
2007-08-29 |
2021-06-08 |
梅特希尔基因公司 |
Inhibitors of protein tyrosine kinase activity
|
AU2008325608B2
(en)
|
2007-11-09 |
2013-03-14 |
Eisai R & D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
EP2248804A4
(en)
*
|
2008-01-29 |
2014-09-10 |
Eisai R&D Man Co Ltd |
Combined use of angiogenesis inhibitor and taxane
|
PL2268623T3
(en)
*
|
2008-03-17 |
2015-10-30 |
Ambit Biosciences Corp |
Quinazoline derivatives as raf kinase modulators and methods of use thereof
|
TWI447108B
(en)
|
2009-01-16 |
2014-08-01 |
Exelixis Inc |
Malate salts of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof
|
UA108618C2
(en)
|
2009-08-07 |
2015-05-25 |
|
APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
|
US7998973B2
(en)
*
|
2009-11-13 |
2011-08-16 |
Aveo Pharmaceuticals, Inc. |
Tivozanib and temsirolimus in combination
|
ES2573515T3
(en)
|
2010-06-25 |
2016-06-08 |
Eisai R&D Management Co., Ltd. |
Anti-tumor agent that uses compounds with combined kinase inhibitory effect
|
US20130225581A1
(en)
*
|
2010-07-16 |
2013-08-29 |
Kyowa Hakko Kirin Co., Ltd |
Nitrogen-containing aromatic heterocyclic derivative
|
EA022873B1
(en)
|
2010-10-27 |
2016-03-31 |
Новартис Аг |
Use of vegf-r2 inhibitor for the treatment of ocular vascular disease
|
RU2580609C2
(en)
|
2011-04-18 |
2016-04-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Anticancer therapeutic agent
|
ES2705950T3
(en)
|
2011-06-03 |
2019-03-27 |
Eisai R&D Man Co Ltd |
Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds
|
CN102532116B
(en)
*
|
2011-08-09 |
2015-01-21 |
武汉迈德森医药科技有限公司 |
Synthesis method of anti-tumor targeted therapeutic drug tivozanib
|
CN102408411B
(en)
*
|
2011-09-19 |
2014-10-22 |
北京康辰药业股份有限公司 |
Hydroximic acid compound containing quinolyl and preparation method thereof, and drug composition containing the compound and use thereof
|
CN102408418A
(en)
*
|
2011-10-21 |
2012-04-11 |
武汉迈德森医药科技有限公司 |
Tivozanib acid salt and preparation method and crystal form thereof
|
EP2626073A1
(en)
|
2012-02-13 |
2013-08-14 |
Harmonic Pharma |
Compound for use in the prevention and/or treatment of a neurogenerative disease or a disease involving an activation of phosphodiesterase-4 (PDE4)
|
EP2937337A4
(en)
|
2012-12-21 |
2016-06-22 |
Eisai R&D Man Co Ltd |
Amorphous form of quinoline derivative, and method for producing same
|
NZ714049A
(en)
|
2013-05-14 |
2020-05-29 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
CN110193009A
(en)
|
2013-07-12 |
2019-09-03 |
伊维希比奥公司 |
Method for treating or preventing ophthalmology disease
|
TWI721954B
(en)
|
2014-08-28 |
2021-03-21 |
日商衛材R&D企管股份有限公司 |
High-purity quinoline derivative and production method thereof
|
EP3789027A1
(en)
|
2015-01-13 |
2021-03-10 |
Kyoto University |
Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis
|
RU2017128583A
(en)
|
2015-02-25 |
2019-03-25 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
METHOD FOR REDUCING THE BITTER OF A QUINOLINE DERIVATIVE
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
AU2016279474B2
(en)
|
2015-06-16 |
2021-09-09 |
Eisai R&D Management Co., Ltd. |
Anticancer agent
|
BR112018006873A2
(en)
|
2015-10-05 |
2018-11-06 |
The Trustees Of Columbia University In The City Of New York |
autophageal flow activators and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
|
WO2018028591A1
(en)
*
|
2016-08-09 |
2018-02-15 |
殷建明 |
Quinoline derivative and use thereof
|
CN106478621B
(en)
*
|
2016-09-30 |
2018-12-25 |
遵义医学院 |
Quinoline or quinazoline derivative, preparation method and applications
|
EP3548007A4
(en)
|
2016-12-01 |
2020-08-12 |
Ignyta, Inc. |
Methods for the treatment of cancer
|
CN108341813B
(en)
*
|
2017-01-24 |
2020-11-17 |
四川大学 |
Substituted 1- (isoxazol-3-yl) -3- (3-fluoro-4-phenyl) urea derivative and preparation method and application thereof
|
CN108530455B
(en)
|
2017-03-01 |
2021-01-12 |
北京赛特明强医药科技有限公司 |
Urea substituted aromatic ring connecting dioxane and quinazoline compound or medicinal salt or hydrate and application as tyrosine kinase inhibitor
|
JP7117323B2
(en)
*
|
2017-04-27 |
2022-08-12 |
アストラゼネカ・アクチエボラーグ |
Phenoxyquinazoline compounds and their use in treating cancer
|
CN110573505B
(en)
|
2017-04-27 |
2023-04-11 |
阿斯利康(瑞典)有限公司 |
C 5 -anilinoquinazoline compounds and their use in the treatment of cancer
|
CN109553612B
(en)
*
|
2017-09-26 |
2021-09-03 |
广西梧州制药(集团)股份有限公司 |
Pyrazolopyrimidine derivative, preparation method thereof and application thereof in medicine preparation
|
JP7018224B2
(en)
|
2018-02-11 |
2022-02-10 |
北京賽特明強医薬科技有限公司 |
Urea-substituted aromatic ring-bonded dioxynoquinoline compounds, their preparation methods and uses
|
EA202191273A1
(en)
|
2018-11-05 |
2021-09-15 |
Авео Фармасьютикалз, Инк. |
USE OF TIVOZANIB FOR THE TREATMENT OF SUBJECTS WITH REFRACTED CANCER
|
EP3903828A4
(en)
|
2018-12-21 |
2022-10-05 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
CA3237696A1
(en)
|
2021-11-08 |
2023-05-11 |
Progentos Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
WO2023096651A1
(en)
|
2021-11-26 |
2023-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods for treating bile duct cancers with tivozanib
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
WO2024095127A1
(en)
|
2022-10-31 |
2024-05-10 |
Pliva Hrvatska D.O.O. |
Solid state forms of tivozanib and process for preparation thereof
|